Kasr Al Ainy Hospital
Cairo, 11865, Egypt
NCT Number: NCT05496179
to compare the effectiveness as well as the safety of prucalopride against metoclopramide as the first line treatment for feeding intolerance in critically ill patients.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1 / Phase 2
Cairo, 11865, Egypt
Provision of nutrition support to the critically ill is now established as an essential part of patient care where aiming toward 100% of the predicted target may have resulted in reduced mortality and increased ventilator-free days in those who are premorbidly malnourished. Despite these reported benefits, clinicians continue to deliver little more than half of the enteral nutrition (EN) they plan to provide, due to gastric motility disorders, patient intolerance and clinical interruptions. Also despite the availability of numerous clinical practice guidelines (CPGs) focused on feeding critically ill patients, observational studies have consistently demonstrated persistent and significant gaps between guideline recommendations and actual nutrition practice. Consequently, underfeeding is prevalent in the intensive care unit (ICU), with patients on average receiving only 60 % of the calories that are prescribed. Moreover, Among the barriers to adequate nutritional supply in the ICU which contributes to nutritional status deterioration, gastrointestinal disorders causing enteral feed intolerance are the most important and the most often mentioned in the literature. when gastric emptying was measured in critically ill patients, 46 % of them had evidence of delayed gastric emptying. Untreated slow gastric emptying has a plethora of clinical consequences such as vomiting, aspiration of gastric contents, pneumonia, and contributes significantly to the frequent interruptions and cessation of EN in the ICU, which results in inadequate nutritional delivery. Studies have shown an association between feeding intolerance, prolonged intensive care unit (ICU) stay, and increased risk of death.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Prokinetic
Other names: Resolor
Prokinetic
Other names: Primperan
Time frame: 7 days
Gastric residual volume as a surrogate to gastric emptying by means of gastric residual volume
Time frame: 7 days
Enteral nutrition volume ratio
Time frame: one month
C reactive protein
Time frame: 3 months
duration of stay in intensive care unit
Time frame: 7 days
occurence of adverse drug events
Ain Shams University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04337710
Enteral Feeding Intolerance, Female Urogenital Diseases and Pregnancy Complications
Birmingham, Alabama, United States
View Trial DetailsNCT05265143
Enteral Feeding Intolerance, Female Urogenital Diseases and Pregnancy Complications
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03795870
Enteral Feeding Intolerance
Rochester, Minnesota, United States
View Trial DetailsNCT03422900
Brain Diseases, Cardiovascular Diseases
Valladolid, Spain
View Trial Details